{
    "nct_id": "NCT04650854",
    "official_title": "An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis",
    "inclusion_criteria": "* Study participant must meet one of the following:\n\n  1. completed MG0003 [NCT03971422]\n  2. required rescue therapy during the Observation Period in MG0003 or\n  3. completed at least 6 visits in MG0004 [NCT04124965]\n* Body weight â‰¥35 kg at Baseline (Day 1)\n* Study participants may be male or female\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Study participant has a known hypersensitivity to any components of the study medication or other anti-neonatal Fc receptor (FcRn) medications\n* Study participant with a known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent tuberculosis infection (LTBI), or current/history of nontuberculous mycobacterial infection (NTMBI)\n* Study participant met any mandatory withdrawal or mandatory study drug discontinuation criteria in MG0003, or MG0004, or permanently discontinued study drug in either study\n* Study participant intends to have a live vaccination during the course of the study or within 8 weeks following the final dose of rozanolixizumab\n* Study participant with severe (defined as Grade 3 on the Myasthenia Gravis-Activities of Daily Living (MG-ADL) scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis",
    "miscellaneous_criteria": ""
}